| Literature DB >> 23777465 |
Bridget Candy1, Michael King, Louise Jones, Sandy Oliver.
Abstract
BACKGROUND: Complex healthcare interventions consist of multiple components which may vary in trials conducted in different populations and contexts. Pooling evidence from trials in a systematic review is challenging because it is unclear which components are needed for effectiveness. The potential is recognised for using recipients' views to explore why some complex interventions are effective and others are not. Methods to maximise this potential are poorly developed.Entities:
Mesh:
Year: 2013 PMID: 23777465 PMCID: PMC3693880 DOI: 10.1186/1745-6215-14-179
Source DB: PubMed Journal: Trials ISSN: 1745-6215 Impact factor: 2.279
Figure 1Flow chart for QCA analysis.
Reducing for the purposes of qualitative comparative analysis (QCA) the number of factors to below 10
| 1. Acknowledging within the intervention that adherence is dynamic. | |
| 2. Paying attention to possible negative social circumstances. | |
| 3. Discussing whether secrecy of disclosing condition is threatened by taking treatment. | |
| 4. Discussing the seriousness of the disease. | |
| 5. Feedback about positive reactions of the body to treatment should be provided. | |
| 6. In cases of depression, this should be treated before starting therapy; substance misuse should be managed as a first priority. | |
| 8. To facilitate to learn to trust in oneself. | |
| 9. To get patients to describe their own behaviour. | |
| 10. To offer good medical follow-up. | |
| 11. Enquire into personal risks factors, and 12. Use insight on personal risk factors became ‘a focus on personal risk factors’; | |
| 13. Discuss ambivalence to medicine, and 14. Discuss acceptance of disease became ‘an exploration of attitudes to drug and/or disease’; | |
| 15. Pointing out the value of treatment to a patient’s life enhances motivation, and 16. Explain the relationship between adherence and disease became ‘emphasis on the value of adherence’; | |
| 17. Clear instructions on how to take medication, and 18. Information appropriate to patient’s understanding became ‘clear or appropriate information’; | |
| 19. Acquire insight into a patient’s social support systems, 20. Counsel patient on how use social support, and 21. Social support has to be substantial and practical became ‘a focus on improving social support’. | |
| 22. Discuss circumstances that lead to forgetting to take treatment. | |
| 23. Emphasise that experiencing no symptoms does not mean to stop taking the drug. | |
| 24. Enhance convenience of taking the drug. | |
| 25. Information on side effects. | |
| a. A focus on personal risk factors. | |
| b. An exploration of attitudes to drug and/or disease. | |
| c. Emphasis on the value of adherence. | |
| d. Clear or appropriate information. | |
| e. A focus on improving social support. |
Pathways identified to effective and ineffective interventions
| The configuration most commonly associated with effectiveness (found in eight trials) involved one factor: ‘a focus on personal risk factors’ (pathway 1: [ | |
| (i) ‘Discuss circumstances that lead to forgetting to take treatment’ and ‘a focus on improving social support’ (pathway 2: [ | |
| Or the absence of: | |
| (i) ‘Discussion relating to not stopping the medication if there are no symptoms’ and ‘improving social support’ (pathway 3: [ | |
| The other configurations involved ‘provision of clear/appropriate information on how to take medication’, with the absence of: | |
| (i) ‘Exploration of attitudes to therapy/disease’ and ‘discussion relating to not stopping taking medication if there are no symptoms’ (pathway 4:[ | |
| Or the absence of: | |
| (ii) ‘Discussion relating to missing a drug’ and ‘discussion relating to not stopping taking medication if there are no symptoms’ (pathway 5: [ | |
| Or the absence of: | |
| (iii) ‘Discussion relating to not stopping taking medication if there are no symptoms’ and ‘improving social support’ (pathway 6: [ | |
| All four configurations (pathways) for the ineffective interventions included the absence of one factor: ‘a focus on personal risk factors’. Two of the configurations also involved the absence of either: | |
| (i) ‘Information on side effects’ and ‘pointing out the value of adherence’ (pathway 1: [ | |
| or | |
| (ii) ‘Pointing out the value of adherence’ and ‘provision of clear or appropriate information’ (pathway 2: [ | |
| In the other two configurations the absence of ‘a focus on personal risk factors’ also involved the presence of either: | |
| (i) ‘Discussion relating to missing a drug’ (pathway 3: [ | |
| (ii) ‘Emphasis that experiencing no symptoms does not mean stopping medication’ (pathway 4: [ |